New Janssen Campaign Developed by and for the LGBTQ+ Community Inspires Action and Empathy for People Living with Depression
TITUSVILLE, NJ, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the launch of Depression Looks Like Me, a campaign aimed at normalizing the conversation about depression in the LGBTQ+ community and empowering people to seek the mental health care they may need. Janssen has partnered with prominent LGBTQ+ voices and leading mental health and LGBTQ+ advocacy organizations to amplify lived experiences across the community and underscore that those living with hard-to-treat depression are not alone. Depression is a serious and chronic health condition that disproportionally affect...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
New Brunswick, NJ (May 12, 2022) -- Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort, Rancho Palos Verdes, CA on Thursday, June 16th. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 1:00 p.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately 48 hours after the live webcast. (Source: Johnson and Johnson)
Source: Johnson and Johnson - May 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company
NEW BRUNSWICK, N.J. May 11, 2022– Johnson & Johnson (the “Company”) (NYSE: JNJ) today announced the appointment of Thibaut Mongon as Chief Executive Officer Designate and Paul Ruh as Chief Financial Officer Designate of the future, listed New Consumer Health Company. As announced in November 2021, the planned separation would create two global leaders – the new Johnson & Johnson and the New Consumer Health Company - that are better positioned to deliver improved health outcomes for patients and consumers through innovation, pursue more targeted business strategies and accelerate growth.This leadership trans...
Source: Johnson and Johnson - May 11, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Discontinues Collaboration and License Agreements with Bavarian Nordic in Hepatitis B and Human Papillomavirus
NEW BRUNSWICK, NJ, May 9, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the termination of its collaboration and license agreements with Bavarian Nordic that leverage Bavarian Nordic’s MVA-BN® (Modified Vaccinia Ankara - Bavarian Nordic) technology to develop potential vaccines against the hepatitis B virus and human papillomaviruses. Janssen remains committed to its strong collaboration with Bavarian Nordic in the quest to prevent and cure infectious diseases – with collaborations in HIV and Ebola still ongoing.No clinical studies in hepatitis B have been initiated by Janssen ut...
Source: Johnson and Johnson - May 9, 2022 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Updates U.S. COVID-19 Vaccine Fact Sheet
NEW BRUNSWICK, NJ, May 5, 2022 - Our number one priority is the safety and well-being of those who use the Johnson & Johnson COVID-19 vaccine. Johnson & Johnson, in close coordination with the U.S. Food and Drug Administration (FDA), has updated its U.S. COVID-19 Vaccine Fact Sheet to increase awareness about the risk of thrombosis with thrombocytopenia syndrome (TTS), a rare but potentially life-threatening condition. Language about the risk of TTS has been added to the first page of the Fact Sheet to increase its prominence. Following the update to the Fact Sheet, the Johnson & Johnson COVID-19 vaccine is now...
Source: Johnson and Johnson - May 5, 2022 Category: Pharmaceuticals Source Type: news
MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development
Spring House, Pa., May 5, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the Measurable residual disease Partnership and Alliance in Acute myeloid leukemia Clinical Treatment (MPAACT), an industry-led research alliance founded in 2018 between Janssen Research & Development, LLC, Genentech (a member of the Roche Group), Novartis, and Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, and recently expanded with additional members Amgen, AbbVie, and Kronos Bio, is advancing efforts to establish measurable residual disease (MRD) as a surrogate endpoint for overall ...
Source: Johnson and Johnson - May 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson to Participate in the Bernstein 38th Annual Strategic Decisions Conference
New Brunswick, NJ (May 2, 2022) - Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1st, at the New York Hilton Midtown in New York. Joaquin Duato, Chief Executive Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.comA webcast replay will be available approximately 48-hrs after the live webcast. (Source: Johnson and Johnson)
Source: Johnson and Johnson - May 2, 2022 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)
Cape Town, South Africa, April 25, 2022 – Johnson & Johnson (the Company) today announced the launch of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, in Cape Town, South Africa. This marks the latest expansion of the J&J Centers for Global Health Discovery (J&J Centers), a global network of research collaborations between the Company and leading research institutions to accelerate translational and discovery research to address some of the world’s most pressing global health challenges. The Sa...
Source: Johnson and Johnson - April 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson to Participate in the UBS Global Healthcare Conference
New Brunswick, NJ (April 20th, 2022) -- Johnson & Johnson (NYSE: JNJ) will participate in the UBS Global Healthcare Conference on Tuesday, May 24th. Mathai Mammen, Executive Vice President, Pharmaceuticals R&D, will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. A webcast replay will be available approximately 48 hours after the live webcast. (Source: Johnson and Johnson)
Source: Johnson and Johnson - April 20, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Johnson & Johnson Statement on Alabama Opioid Settlement Agreement
NEW BRUNSWICK, NJ, April 19, 2022 - Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies (collectively, the “Company”) today announced a settlement agreement with the State of Alabama and its participating subdivisions resolving current and future opioid-related claims against the Company. With this agreement, the Company is removed from filed cases in the state.The $77 million settlement with Alabama is consistent with the framework of the recently finalized nationwide opioid settlement agreement. This settlement is not an admission of any liability or wrongdoing and the Company will continue to d...
Source: Johnson and Johnson - April 19, 2022 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Reports Q1 2022 Results
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-based commitment to delivering transformative healthcare solutions to patients and customers around the world,” said Joaquin Duato, Chief Executive Officer. “Looking ahead, I remain confident in the future of Johnson & Johnson as we continue advancing our portfolio and inno...
Source: Johnson and Johnson - April 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Johnson & Johnson Announces Dividend Increase of 6.6%
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson today announced that its Board of Directors has declared a 6.6% increase in the quarterly dividend, from $1.06 per share to $1.13 per share.“In recognition of our 2021 results, strong financial position, and confidence in the future of Johnson & Johnson, the Board of Directors has voted to increase the quarterly dividend for the 60th consecutive year,” said Joaquin Duato, Chief Executive Officer of the company.At the new rate, the indicated dividend on an annual basis is $4.52 per share compared to the previous rate of $4.24 per share. The next quarterl...
Source: Johnson and Johnson - April 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Johnson & Johnson Statement on West Virginia Opioid Settlement Agreement
NEW BRUNSWICK, N.J., April 18, 2022 - Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies (collectively, the “Company”) today announced a settlement agreement with the State of West Virginia and its participating subdivisions resolving their opioid-related claims against the Company. With this agreement, the Company is removed from the trial ongoing in Kanawha County, West Virginia.The $99 million settlement will directly support local community efforts to seek meaningful progress in addressing the opioid crisis in West Virginia. This settlement is not an admission of liability or wrongdoing and m...
Source: Johnson and Johnson - April 18, 2022 Category: Pharmaceuticals Source Type: news
Johnson & Johnson to Participate in the BofA Securities 2022 Healthcare Conference
New Brunswick, N.J., April 7, 2022 – Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities 2022 Healthcare Conference at the Encore Hotel in Las Vegas, Nevada on Wednesday, May 11th. Ashley McEvoy, Executive Vice President, Worldwide Chairman, MedTech will represent the Company in a session scheduled at 3:40 p.m. (Eastern Time). This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at www.investor.jnj.com. A webcast and podcast replay will be available approximately 48 hours after the live webcast. (Source: Johnson and Johnson)
Source: Johnson and Johnson - April 7, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Announces Health Canada Approval of RYBREVANT ® (amivantamab), the First and Only Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Toronto, ON, April 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving RYBREVANT® (amivantamab), a fully-human, bispecific antibody, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.[i] Health Canada NOC/c is granted to promising new therapies for patients diagnosed with serious, life-threate...
Source: Johnson and Johnson - April 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
